Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Inc. (NYSE: DGX) is a leading provider of diagnostic testing, information, and services in the United States, enabling people to make informed health decisions. The company provides diagnostic insights derived from the world’s largest database of clinical lab results, which aids in identifying and treating diseases, promoting healthy behaviors, and improving healthcare management.
Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States. Its workforce of nearly 50,000 employees is dedicated to transforming lives by providing actionable diagnostic insights. The company offers the broadest test menu available, with over 3,000 different tests, and has a strong focus on cancer diagnostics, anatomic pathology, and interpretive consultations through its medical and scientific staff of approximately 900 M.D.s and Ph.D.s.
In recent years, Quest Diagnostics has been at the forefront of innovation in diagnostic testing. The company has significantly invested in AI and digital pathology to enhance the accuracy and efficiency of cancer diagnoses. A notable collaboration with PathAI aims to accelerate the adoption of digital and AI pathology technologies, thereby improving the quality, speed, and efficiency of diagnosing cancer and other diseases. This partnership includes the acquisition of PathAI Diagnostics’ state-of-the-art digitized laboratory in Memphis, Tennessee, which will serve as Quest’s AI and digital R&D and solutions center.
Financially, Quest Diagnostics has shown robust performance, with annual revenues reaching $7.4 billion in 2014. The company continues to strengthen its market presence through strategic acquisitions and partnerships, expanding its services and enhancing its capabilities in specialized pathology services. The integration of digital and AI technologies across its operations has improved quality, efficiency, and customer satisfaction, positioning Quest Diagnostics as a leader in the diagnostic services industry.
Quest Diagnostics' extensive clinical testing network includes roughly 2,300 patient service centers, numerous doctors' offices, and hospitals nationwide. The company also provides clinical trials testing, risk assessment services, and information technology solutions through its diagnostic solutions segment.
By leveraging its comprehensive diagnostic insights, Quest Diagnostics aims to empower individuals and healthcare providers to make informed decisions that lead to better health outcomes, ultimately contributing to a healthier world.
Takeda has launched the CDPATH™ program, a personalized prognostic tool designed for Crohn's disease patients in the U.S. This tool predicts the risk of developing serious complications within three years using blood tests, and it's offered at no cost to eligible adult patients. The program aims to facilitate shared decision-making between patients and healthcare providers by integrating patient-specific markers with clinical assessments. CDPATH is available through over 2,500 locations nationwide, enhancing patient-centered care for over three million people affected by inflammatory bowel disease.
Quest Diagnostics (NYSE: DGX) is set to present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:40 p.m. Eastern Time. CEO-elect Jim Davis and CFO Sam Samad will outline the company's vision and capital strategies. The presentation will be accessible via a live webcast on their investor relations page and archived for later viewing until October 13, 2022. Quest Diagnostics is a premier provider of diagnostic services, serving a significant portion of healthcare professionals and patients in the U.S.
Quest Diagnostics (NYSE: DGX) has received emergency use authorization (EUA) from the FDA for its lab-developed test specifically designed to detect Monkeypox virus DNA. This marks the first EUA granted for a commercially available Monkeypox test in the U.S. The Quest Monkeypox PCR test detects DNA from Monkeypox and non-variola Orthopoxvirus in lesion swabs, providing a crucial tool for diagnosis amid the ongoing public health emergency. The test's dual-target capability minimizes false negatives, enhancing reliability. It is now available nationwide, complementing public health laboratory efforts.
uMETHOD partners with Getlabs to provide at-home lab services for Arizona patients, enhancing accessibility for those with cognitive decline, including mild dementia and Alzheimer's disease. In just one month, mobile service usage quadrupled in the Greater Phoenix area. This partnership aims to improve treatment compliance and patient independence by connecting diagnostics with actionable treatment plans through uMETHOD's RestoreU program. With over 150,000 Arizonans affected by cognitive decline, this initiative addresses a critical healthcare need while collaborating with Sonora Quest Laboratories for efficient sample testing.
Quest Diagnostics has launched a new obstetrics laboratory test panel that incorporates hepatitis C (HCV) screening, following a study indicating that under 41% of pregnant individuals were screened for HCV in 2021. This initiative stems from a Quest Health Trends® study conducted with the CDC, highlighting significant screening gaps, particularly among Medicaid beneficiaries. The new panel aims to close this gap and align with guidelines recommending routine HCV screening during pregnancy, addressing rising HCV infections in the U.S. and potentially improving health outcomes for both mothers and infants.
Paige partners with Sonora Quest Laboratories to implement a digital pathology workflow in Arizona, enhancing diagnostic processes and patient care. The initiative aims to streamline diagnostics and reduce errors through Paige's advanced AI solutions, including the FDA-approved Paige Prostate Detect. Sonora Quest, part of a leading integrated laboratory system, conducts over 97 million tests annually with a robust test menu. This collaboration is expected to improve the overall healthcare experience and accelerate precision diagnoses.
Quest Diagnostics (NYSE: DGX) declared a quarterly cash dividend of $0.66 per share, payable on October 19, 2022. Shareholders of record on October 4, 2022 will receive this dividend, reflecting the company's commitment to returning value to its investors. Quest Diagnostics continues to lead in diagnostic information services, supporting health outcomes with insights derived from its extensive database. This dividend announcement indicates confidence in ongoing business performance and the company's financial health.
Quest Diagnostics is launching the "Es Tu Poder" initiative to enhance healthcare access for the Hispanic community in Texas, targeting cities like San Antonio and Houston. The program aims to combat higher disease rates among Hispanics, offering educational tools and resources in collaboration with healthcare organizations. Dr. Romeo Solano emphasizes the initiative's role in addressing health disparities exacerbated by COVID-19, particularly in areas like the Rio Grande Valley. With over 10 million Hispanics in Texas, this project focuses on empowering individuals to take control of their health.
A recent Quest Diagnostics study highlights that only 1 in 3 patients with latent tuberculosis (TB) were also tested for chronic hepatitis B (HBV), despite shared risk factors. The analysis evaluated nearly 23 million lab tests from 2016 to 2020, revealing a significant gap in concurrent testing.
This raises concerns as TB therapies can induce liver damage in co-infected patients. Notably, 19.6% of those with chronic HBV also had latent TB, emphasizing the need for routine HBV screening prior to TB treatment.
FAQ
What is the current stock price of Quest Diagnostics (DGX)?
What is the market cap of Quest Diagnostics (DGX)?
What does Quest Diagnostics do?
How many people does Quest Diagnostics serve annually?
What are some recent achievements of Quest Diagnostics?
What kind of tests does Quest Diagnostics offer?
What is the company's approach to innovation?
How extensive is Quest Diagnostics' clinical testing network?
What role do partnerships play at Quest Diagnostics?
How does Quest Diagnostics contribute to healthcare management?
What are the company’s future plans?
How does Quest Diagnostics ensure the quality of its services?
